Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dmitriy Grinshpun

Neurology Brooklyn, NY Medical Doctor

NPI 1265445639 CMS profile 11415

174 Brighton 11Th St, Brooklyn, NY 11235

Open in the dashboard

General payments

$84,428

1,319 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dmitriy Grinshpun of Brooklyn, NY is reported in the CMS Open Payments database as having received $84,428 across 1,319 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $11,901 188
2024 General $9,724 193
2023 General $13,834 204
2022 General $12,243 210
2021 General $10,481 241
2020 General $14,033 143
2019 General $12,211 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dmitriy Grinshpun
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Dmitriy Grinshpun were reported at $11,901. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Dmitriy Grinshpun Neurology median Middle half National median
2019 $12,211 $474 $118–$2,177 $163
2020 $14,033 $367 $82–$2,309 $114
2021 $10,481 $438 $104–$2,547 $132
2022 $12,243 $442 $103–$2,388 $149
2023 $13,834 $464 $119–$2,312 $160
2024 $9,724 $468 $119–$2,323 $164
2025 $11,901 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $38,527 217 payments
  2. Allergan Inc. $13,050 85 payments
  3. Avanir Pharmaceuticals, Inc. $9,979 35 payments
  4. UCB, Inc. $2,215 141 payments
  5. SK Life Science, Inc. $2,108 77 payments
  6. Amneal Pharmaceuticals LLC $1,511 32 payments
  7. Biogen, Inc. $1,462 67 payments
  8. Neurocrine Biosciences, Inc. $1,411 55 payments
  9. Otsuka America Pharmaceutical, Inc. $1,195 35 payments
  10. Eisai Inc. $979 42 payments
  11. Other $11,990 533 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,325 50 payments
  2. Food and Beverage $30,373 1,258 payments
  3. Honoraria $700 1 payment
  4. Education $28 9 payments
  5. Travel and Lodging $2 1 payment
Products named General payments · program years 2019–2025
  1. UBRELVY Neuroscience $34,786 95 payments
  2. QULIPTA $15,460 63 payments
  3. UBRELVY Neuroscience $11,780 24 payments
  4. NUEDEXTA $9,979 35 payments
  5. Briviact $1,354 87 payments
  6. RYTARY $1,292 24 payments
  7. BOTOX $1,163 15 payments
  8. INGREZZA $1,152 40 payments
  9. Fycompa $892 38 payments
  10. REXULTI $891 24 payments
  11. Other $19,554 920 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 117 drugs

Part D claims

18,381

Median for Neurology: 833

Drug cost

$3,208,581

Median for Neurology: $202,670

Branded share of claims

23.1%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ubrelvy Ubrogepant Brand 344 $534,133
Qulipta Atogepant Brand 261 $442,604
Nuedexta Dextromethorphan Hbr/Quinidine Brand 148 $225,152
Diclofenac Sodium Generic 720 $194,619
Gocovri Amantadine Hcl Brand 44 $189,894
Nuplazid Pimavanserin Tartrate Brand 14 $150,442
Vraylar Cariprazine Hcl Brand 102 $143,544
Nourianz Istradefylline Brand 32 $105,566
Neupro Rotigotine Brand 98 $95,811
Dihydroergotamine Mesylate Generic 99 $90,376

The 10 drugs with the highest cost, of 117 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$601,755

Of which drugs: $100,492

Medicare patients

858

Average age 76

Services billed

25,211

547 women, 311 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 73%
Depression 60%
Ischemic heart disease 53%
Heart failure 35%
Alzheimer's or dementia 34%
Chronic kidney disease 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 37 20,100 $100,199
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 80 383 $294

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$4,502 344 —
BOTOX
$832 — 20,100
Gocovri
$386 44 —
REXULTI
$332 59 —
NOURIANZ
$299 32 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

1,319 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record